3 active not recruiting, 2 recruiting, 2 terminated, 2 withdrawn. 6 Phase 2, 3 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
| Not applicable | 2 | Recruiting 2 |
Follow this condition Literature Review of Breast Inflammatory Carcinoma trials Research Report on Breast Inflammatory Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial Exercise Intervention, Educational Intervention, Supportive Care - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | Wake Forest University Health Sciences | 120 | 2026-10-02 | 2026-10-06 |
| SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Carboplatin, Pembrolizumab, Transferrin Receptor-Targeted Liposomal p53 cDNA - Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Phase 1 | Withdrawn | Northwestern University | 2022-11-10 | 2022-11-15 | |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer Biospecimen Collection, Olaparib, Radiation Therapy - Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 300 | 2019-01-18 | 2026-09-29 |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma Indocyanine Green, Lymphangiography, Lymphovenous Bypass - Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 252 | 2018-08-14 | 2026-05-26 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 280 | 2017-03-31 | 2026-06-30 |
| Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab - Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 36 | 2017-01-26 | 2026-06-11 |
Inflammatory Breast Neoplasms (9) · Breast Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Melanoma (1) · Unilateral Breast Neoplasms (1)
Breast Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Breast Neoplasms (6) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Neoplasms (1)
Cyclophosphamide (3) · pembrolizumab (3) · Carboplatin (2) · Doxorubicin (2) · Paclitaxel (2) · Specimen Handling (2) · Taxes (2) · 2C4 antibody (1) · Accelerometry (1) · Clostridium perfringens epsilon-toxin (1) · Colony-Stimulating Factors (1) · Early Intervention, Educational (1) · Educational Status (1) · Exercise Test (1) · Indocyanine Green (1)
M.D. Anderson Cancer Center (5) · Academic and Community Cancer Research United (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Wake Forest University Health Sciences (1)
United States (9) · Canada (1) · Puerto Rico (1)
Azadeh Nasrazad, MD,PHD (1) · Bora Lim, MD (1) · Glenn Lesser, MD (1) · Kathryn J Ruddy (1) · Mark Schaverien (1) · Massimo Cristofanilli, MD, FACP (1) · Rachel Layman, MD (1) · Reshma Jagsi (1) · Sadia Saleem (1)
P30CA015083 (1), P30CA016672 (1), P30CA060553 (1), U10CA180888 (1)